Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Tuberculosis (TB) is the world's second leading infectious killer. Cases of multidrug-resistant
(MDR-TB) and extremely drug-resistant (XDR-TB) have increased globally. Therapeutic …

Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of
Mycobacterium tuberculosis, is an increasingly serious problem worldwide. Here we …

Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on
pharmacokinetic, toxicity, and cost considerations. Available data in mice and humans …

For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex
lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular …

The aim of these guidelines is to describe a practical but evidence-based approach to the
diagnosis and treatment of central nervous system tuberculosis in children and adults. We …

Tuberculosis (TB) remains a leading cause of death globally. Dissemination of TB to the
brain results in the most severe form of extrapulmonary TB, tuberculous meningitis (TBM) …

Drugs for tuberculosis are inadequate to address the many inherent and emerging
challenges of treatment. In the past decade, ten compounds have progressed into the …

Abstract (See the editorial commentary by Dartois, on pages 1827–9.) Background. It is
believed that nonadherence is the proximate cause of multidrug-resistant tuberculosis (MDR …

Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at
least 6 months of multidrug treatment to achieve cure. However, the lack of reliable data on …